Global Injectable Drug Delivery Market Key Players 2018: SWOT Analysis, Market Drivers, Challenges, Growth Opportunities, Technological Changes 2018-2025

Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.
Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market
Covered in this report
The report covers the present scenario and the growth prospects of the global injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

The key market players for global injectable drug delivery market are listed below:
• Baxter International, Inc.,
• Becton Dickinson and Company,
• Gerresheimer AG,
• Pfizer, Inc.,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.
• Ypsomed,
• Bespak
Have Any Query? Ask Our Expert: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market

The market is further segmented into:
• Type
• Usage Pattern
• End-User
• Mode of Administration
• Distribution Channel
• Application
• Geography
The global injectable drug delivery market is segmented on of type, portability, type, product type, application, usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.
The global injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 75.7% market share in 2018, growing at a CAGR of 12.4% and will cross USD 837,873.64 million by 2025

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 50.1% market share in 2018, growing at a CAGR of 12.1% and will cross USD 540,977.35 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 13.6% in the forecast period, and is expected to reach USD 265,145.17 million in 2025 from USD 82,915.00 million in 2017
Questions? We’ll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-injectable-drug-delivery-market

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 93.2% market share in 2018, growing at a CAGR of 12.5% and will cross USD 1,036,829.49 million by 2025.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 46.8% market share in 2018, growing at a CAGR of 12.8% and will cross USD 532,193.0 million by 2025.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 62.6% market share in 2018, growing at a CAGR of 12.5% and will cross USD 693,323.05 million by 2025.
On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 69.2% market share in 2018, growing at a CAGR of 12.7% and will cross USD 780,682.75 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 13.5% in the forecast period, and is expected to reach USD 142,617.48 million in 2025 from USD 44,812.56 million in 2017
Based on geography, the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others.
Based on geography, the Global injectable drug delivery market is segmented into geographical regions, such as,
• North- America
• South America
• Europe
• Asia-Pacific
• Middle East and Africa

TABLE OF CONTENTS GLOBAL INJECTABLE DRUG DELIVERY MARKET
1. INTRODUCTION

1.1. OVERVIEW OF GLOBAL INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET

3.2. RESTRAINTS

3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK
3.3. OPPORTUNITY
3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS
3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS
3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES
3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL INJECTABLE DRUG DELIVERY MARKET, REGULATORY

6.1. OVERVIEW

6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)

7. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY TYPE

7.1. OVERVIEW

7.2. INJECTABLE DRUG DELIVERY DEVICES

7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS

7.3. INJECTABLE DRUG DELIVERY FORMULATION

7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS

7.3.2. NOVEL DRUG DELIVERY FORMULATIONS

7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION

8. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.1. OVERVIEW
8.2. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
8.3. HORMONAL DISORDERS

8.3.1. INJECTABLE DRUGS FOR DIABETES
8.3.2. INJECTABLE DRUGS FOR ANEMIA
8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)

8.4. ONCOLOGY
8.5. AUTOIMMUNE DISEASES

8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTABLE DRUGS FOR CROHN’S DISEASES
8.5.4. INJECTABLE DRUGS FOR PSORIASIS
8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES

8.6. ORPHAN DISEASE
8.7. OTHER APPLICATIONS

8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTABLE DRUGS FOR HEPATITIS C
8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA

9. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN

10. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM

11. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS

12. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY

13. GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

13.1. OVERVIEW
13.2. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.2.1. U.S. INJECTABLE DRUG DELIVERY MARKET
13.2.2. CANADA INJECTABLE DRUG DELIVERY MARKET
13.2.3. MEXICO INJECTABLE DRUG DELIVERY MARKET

13.3. EUROPE INJECTABLE DRUG DELIVERY MARKET

13.3.1. GERMANY INJECTABLE DRUG DELIVERY MARKET
13.3.2. FRANCE INJECTABLE DRUG DELIVERY MARKET
13.3.3. UK INJECTABLE DRUG DELIVERY MARKET
13.3.4. ITALY INJECTABLE DRUG DELIVERY MARKET
13.3.5. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.6. SPAIN INJECTABLE DRUG DELIVERY MARKET
13.3.7. NETHERLAND INJECTABLE DRUG DELIVERY MARKET
13.3.8. RUSSIA INJECTABLE DRUG DELIVERY MARKET
13.3.9. TURKEY INJECTABLE DRUG DELIVERY MARKET
13.3.10. BELGIUM INJECTABLE DRUG DELIVERY MARKET
13.3.11. REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET

13.4. APAC INJECTABLE DRUG DELIVERY MARKET

13.4.1. JAPAN INJECTABLE DRUG DELIVERY MARKET
13.4.2. CHINA INJECTABLE DRUG DELIVERY MARKET
13.4.3. SOUTH KOREA INJECTABLE DRUG DELIVERY MARKET
13.4.4. INDIA INJECTABLE DRUG DELIVERY MARKET
13.4.5. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET
13.4.6. SINGAPORE INJECTABLE DRUG DELIVERY MARKET
13.4.7. THAILAND INJECTABLE DRUG DELIVERY MARKET
13.4.8. MALAYSIA INJECTABLE DRUG DELIVERY MARKET
13.4.9. INDONESIA INJECTABLE DRUG DELIVERY MARKET
13.4.10. PHILIPPINES INJECTABLE DRUG DELIVERY MARKET
13.4.11. REST OF APAC INJECTABLE DRUG DELIVERY MARKET

13.5. SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.5.1. BRAZIL INJECTABLE DRUG DELIVERY MARKET
13.5.2. REST OF SOUTH AMERICA INJECTABLE DRUG DELIVERY MARKET

13.6. MEA INJECTABLE DRUG DELIVERY MARKET

13.6.1. SOUTH AFRICA INJECTABLE DRUG DELIVERY MARKET
13.6.2. REST OF MEA INJECTABLE DRUG DELIVERY MARKET

14. GLOBAL INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE

14.1. COMPANY SHARE ANALYSIS: GLOBAL

15. COMPANY PROFILES

15.1. BECTON, DICKINSON AND COMPANY
15.2. PFIZER
15.3. BAXTER INTERNATIONAL
15.4. GERRESHEIMER AG
15.5. SCHOTT AG INC.
15.6. ALKERMES INC.
15.7. ANTARES PHARMA
15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)
15.9. ELCAM MEDICAL
15.10. ELI LILLY AND COMPANY
15.11. HASELMEIER
15.12. MYLAN N.V.
15.13. NOVO NORDISK
15.14. OWEN MUMFORD LTD
15.15. SANDOZ INTERNATIONAL GMBH
15.16. SANOFI

16. RELATED REPORTS
Looking for more insights from this report? click the link below @ http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/
Other Market Insights:
North America injectable drug delivery market is expected to reach USD 354.5 billion by 2024 from USD 154.0 billion in 2016, at a CAGR of 11.0% in the forecast period 2017 to 2024.
Read More: http://databridgemarketresearch.com/reports/north-america-injectable-drug-delivery-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.